Sole Source - Production of ChAdOx-1 and MVA expressing mouse gp70

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NIH NCI

Contract Value

Not provided

Codes & Classification
Solicitation Number

75N98026Q00996

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Classification Code

R416

Additional Details
Set Aside

None

Place of Performance

Oxford, Oxfordshire, UNITED KINGDOM

SourceSAM
Documents1
The National Institutes of Health (NIH), specifically the National Cancer Institute’s (NCI) Laboratory of Integrative Cancer Immunology Branch / Immune Regulation and Vaccine Development Section, has issued a combined synopsis/solicitation for a sole-source procurement titled “Production of ChAdOx-1 and MVA expressing mouse gp70” (Solicitation Number: 75N98026Q00996). This procurement seeks to engage the Viral Vector Core at the Pandemic Institute, University of Oxford, for the specialized production of viral vectors critical to ongoing cancer immunology research. **Purpose and Scope:** The primary objective of this procurement is to support the development of a vaccine targeting glioblastoma and breast cancer brain metastasis. The project requires the design and production of two viral vectors: a chimpanzee adenovirus (ChAdOx-1) and a Modified Vaccinia Ankara (MVA), both engineered to express a codon-optimized gene cassette encoding mouse gp70 and the mouse class II major histocompatibility complex invariant chain (Ii). These vectors are essential for preclinical studies in syngeneic orthotopic mouse models, where they have demonstrated the ability to induce robust, tumor-specific CD8 T cell responses and significantly prolong survival in tumor-bearing animals. **Key Requirements and Deliverables:** The contractor will be responsible for: - Designing and constructing a codon-optimized gene expression cassette for mouse gp70 and Ii. - Producing a ChAdOx-1 viral vector encoding the specified gene construct. - Producing an MVA viral vector encoding the same gene construct. All deliverables must be completed within a six-month period from the date of award. Deliverables and progress reports are to be submitted to the designated Contracting Officer’s Representatives, Alan Peigh and Sharon Bargo, Ph.D. Payment will be made on a net 30-day basis following acceptance of deliverables and proper invoicing. **Contracting Entity and Location:** The contracting office is the Department of Health and Human Services, National Institutes of Health, located at 6701 Rockledge Drive, Bethesda, MD 20817, USA. The place of performance for the production activities is Oxford, Oxfordshire, United Kingdom (GB-OXF). **Classification and Codes:** - NAICS Code: 541714 – Research and Development in Biotechnology (except Nanobiotechnology) - Small Business Size Standard: 1,000 employees - Product Service Code: R416 **Procurement Type and Special Considerations:** This is a new requirement, not a follow-on to any previous contract. The acquisition will be processed as a sole-source award under FAR 13.106-1(b)(1) and FAR 6.302-1, as the Viral Vector Core at the University of Oxford is the only known source with the proprietary technology and capability to produce the required chimpanzee adenovirus-based vectors. The contract will be awarded as a firm fixed price purchase order. While this notice is not a request for competitive quotations, interested parties—particularly small businesses—may submit capability statements or proposals for consideration. All responses must be in writing and received by 2:00 PM EDT on August 24, 2026. Submissions and inquiries should be directed to Mary Muir ([email protected]) and Cherie Wells ([email protected]). Only written communications will be accepted; phone calls will not be considered. **Additional Information:** - Only one award will be made. - American contractors must be registered in the System for Award Management (SAM) to be eligible for award. - The government reserves the right to determine whether to proceed with a competitive procurement based on responses received. - The Statement of Work detailing the full requirements is attached to the notice. **Summary:** This procurement represents a critical step in advancing cancer vaccine research by leveraging unique, proprietary viral vector technology. Contractors with expertise in viral vector production, particularly those with access to chimpanzee adenovirus platforms, should carefully review the requirements and consider their ability to meet the technical and timeline demands of this project. For further details, reference RFQ# 75N98026Q00996 and consult the official notice at [SAM.gov](https://sam.gov/opp/472cf6bb55fc4cd2ba2dcaa74b09d877/view).